Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2000-01-28
2002-08-13
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S046000, C514S049000, C514S050000, C514S051000, C514S885000, C514S908000
Reexamination Certificate
active
06432924
ABSTRACT:
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to an active agent of the formula I and to treating a disorder associated in part with the overexpression of cytidine deaminase or deoxycytidine deaminase, comprising administering 5-methyl-2′,3′-dideoxy-3′-azidocytidine (5mAZC), analog thereof or a pharmaceutically effective salt thereof to a subject in need of such treatment in an amount effective to treat the disorder and ameliorate its symptoms.
The overexpression of cytidine deaminase (CD) is associated with a number of human disorders. For example, certain kinds of leukemias are refractory to the widely used anti-cancer agent cytosine arabinoside (araC). The lack of response to araC has been found to be due primarily either to inactivation of the deoxycytidine kinase gene locus (whose product is required for activation of araC to its cancer-killing form), or to the overexpression of cytidine deaminase or deoxycytidine deaminase (which deactivates araC by deaminating it to an inactive form, araUracil). There is currently no adequate treatment to overcome this resistance to araC due to cytidine deaminase or deoxycytidine deaminase overexpression.
The overexpression of cytidine deaminase is also implicated in the infective cycle of the human immunodeficiency virus (HIV), the virus implicated in AIDS. The initial states of HIV infection are characterized by the overexpression of cytidine deaminase by the CD-4+T lymphocytes targeted by the virus. The elimination of this original set of infected cells could be critically important in controlling the level of subsequent infection.
Currently, one treatment for HIV infection and AIDS is the administration of 3′-azido-3′deoxythymidine associated with this treatment. Problems with toxicity, however, have been associated with this treatment. Such toxicity occurs in part due to the fact that AZT is administered systemically, and damages host cells in all replicating tissue compartments.
There is currently a need for a treatment for HIV infection that has the same or improved efficacy of AZT, without the side effects associated with toxicity. One solution to this problem would be a prodrug for AZT which exhibited reduced toxicity to replicating cells, and was preferentially activated to its virus-killing form (AZT) in HIV-infected cells.
In addition, inflammatory cells associated with the symptoms of arthritis have also been shown to overexpress cytidine deaminase.
It would therefore be desirable to provide a relatively non-toxic prodrug that is preferentially activated to a metabolite that is toxic to arthritis mediating inflammatory cells.
SUMMARY OF THE INVENTION
A method of treating a disorder associated with the overexpression of cytidine deaminase or deoxycytidine deaminase comprises administering to a subject in need of such treatment, of 5-methyl-2′,3′dideoxy-3′azidocytidine (5mAZC), analog thereof or pharmaceutically acceptable salts thereof, hereinafter referred to as the “active compound”, an amount effective to treat the disorder.
A method of treating a disorder associated with the overexpression of cytidine deaminase or deoxycytidine deaminase comprises administering to a subject in need of the treatment, an amount of a compound of the chemical formula I
wherein
X and X
1
are each independently C or N;
R
1
is lower alkyl, lower alkenyl, lower alkynyl, halogen, or haloalkyl; and
R
2
is H, —N
3
, —OH, amino, or halogen;
or a pharmaceutically acceptable salt thereof, effective to treat the disorder.
A method of combating leukemia resistant to cytosine arabinoside (araC) comprises administering to a subject in need of the treatment an anti-araC resistant leukemia effective amount of a compound of the chemical formula I.
A method of combating HIV-infection comprises administering to a subject in need of the treatment an anti-HIV effective amount of a compound of the chemical formula I.
A method of combating arthritis comprises administering an anti-arthritis effective amount of a compound of the chemical formula I to an arthritic subject.
A method of combating a cancer associated with the overexpression of cytidine deaminase, comprising administering to a subject in need of the treatment an anti-cancer effective amount of a compound of the chemical formula I.
The agent of this invention is suitable for the preparation of medicament for application in the treatments given above. The medicaments are provided in the form of oral, parenteral, topical, and transdermal formulations, as well as an implant and in the form of a kit.
REFERENCES:
patent: 3891623 (1975-06-01), Vorbrüggen et al.
patent: 4788181 (1988-11-01), Driscoll et al.
patent: 5079235 (1992-01-01), Purifoy et al.
patent: 5084445 (1992-01-01), Chu et al.
patent: 5215971 (1993-06-01), Datema et al.
patent: 5576429 (1996-11-01), Johansson et al.
patent: 6136791 (2000-10-01), Nyce
T. Kulikowski et al.; Preparation and Properties of N4-Alkyl Analogues of 5-Methyl-2'-Deoxycytidine, Their 5'-Mono and Triphosphates, and N4-Alkyl Derivatives of 1,5-Dimethylcytosine,ACTA Biochimica Polonica16:201-217 (1969).
J. J. Fox et al.;Thiation of Nucleosides. II. Synthesis of 5-Methyl-2'-deoxycytidine and Related Pyrimidine Nucleosides, 81:178-187 (1959).
T. Lin et al.; Synthesis and Biological Activity of Various 3+-Azido and 3'-Amino Analogues of 5-Substituted Pyrimidine Deoxyribonucleosides,J. Med. Chem.26, No. 12:1691-1696 (1983).
C. K. Chu et al.; Structure-Activity Relationships of Pyrimidine Nucleosides as Antiviral Agents for Human Immunodeficiency Virus Type 1 in Peripheral Blood Mononuclear Cells,J. Med. Chem.32, No. 3:612-617 (1989).
C. Kim et al.; Potential Anti-AIDS Drugs. 2',3'-Dideoxycytidine Analogues,J. Med. Chem30:862-866 (1987).
F.D. Boudinot et al.; Pharmacokinetics and Metabolism of 3'Azido-2',3'-Dideoxy-5'-Methyl Cytidine in Rhesus Monkeys,Drug Metabolism and Disposition21(5):855-860 (1993).
Appleboom, J. et al., “Purine Enzyme Levels in Rheumatoid Arthritis,” The Journal of Rheumatology, 1985; 12:6, 1075-1077.
Thompson, P.W., et al., “Cytidine deaminase activity as a measure of acute inflammation in rheumatoid arthritis,” Annals of the Rheumatic Diseases, 1986; 45, 9-14.
Stancikova, M., Rovensky, J., “Effect of Cyclosporin on the Activity of Cytidine Deaminase and Adenosine Doaminase in the Serum and Polymorphonuclear Leukocytes of Patients with Rheumatoid Arthritis,” Int. J. Tiss. Reac., XV(4) 169-174 (1993).
Geborek, P., et al., “Cytidine deaminase and lactoferrin in inflammatory synovial fluids, Indicators of local polymorphonuclear cell function?” Medical Abstract: Br J Rheumatol, vol. 31, No. 4, pp. 235-240, Apr. 1992, England.
McCarthy, D.A., ET AL., “Morphological evidence that activated polymorphs circulate in the peripheral blood of patients with rheumatoid arthritis,” Medical Abstract: Ann Rheum Dis, vol. 51, No. 1, Jan. 1992, pp. 13-18, England.
Helliwell, P.S., et al., “Cytidine deaminase activity, C reactive protein, histidine, and erythrocyte sedimentation rate as measures of disease activity in psoriatic arthritis,” Medline Abstract: Ann Rheum Dis, vol. 50, No. 6, Jun. 1991, pp. 362-365, England.
Thompson, P.W., et al., “Evaluation of a simple method for the measurement of cytidine deaminase in serum and comparison with a reference method,” Medline Abstract: Clin Chim Acta, vol. 192, No. 1, Nov. 15. 1990, pp 55-59, Netherlands.
Mansson, B., et al., “Cytidine deaminase activity in synovial fluid of patients with rheumatoid arthritis: relation to lactoferrin, acidosis, and cartilage proteoglycan release.” Medline Abstract: Ann Rheum Dis, vol. 49, No. 8, Aug. 1990. pp. 594-597, England.
James. I, et al., “Determination of serum cytidine deaminase activity using ion-pair reversed-phase liquid chromatography,” Medline Abstract: J Chromalogr, vol. 495, Oct. 27, 1989, pp. 105-112, England.
Jones, D.D., et al. “Serum cytidine deaminse assay—some pitfalls.” Medline Abstract: Ann Rheum Dis. vol. 45, No. 1,
Amzel, Esq. Viviana
East Carolina University
Wilson James O.
LandOfFree
Method of treating disorders characterized by overexpression... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating disorders characterized by overexpression..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating disorders characterized by overexpression... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2945748